Pub Date : 2026-04-01Epub Date: 2025-09-17DOI: 10.1016/j.arcmed.2025.103321
Azmavet M. Güemes-González , Lourdes A. Arriaga-Pizano , Rommel Chacón-Salinas , Isabel Wong-Baeza , Eduardo Ferat-Osorio
Intestinal permeability is the process by which certain substances pass through the intestinal barrier and enter the bloodstream to reach the tissues and organs where they are needed. This vital process is regulated by various physiological mechanisms, depending on the type of molecule being translocated, from ions and water molecules to large peptides and vitamins. However, under certain conditions, intestinal permeability can increase, exposing the body to the passage of unwanted molecules and pathogenic microorganisms. The various mechanisms involved in increased intestinal permeability include the zonulin pathway, intestinal epithelial cell death, intestinal dysbiosis, and transcytosis. Each of these mechanisms is activated by certain stimuli, and may occur in isolation or together. The translocation of molecules and pathogens has been linked to the development or worsening of certain pathologies, such as acute pancreatitis, sepsis, inflammatory bowel diseases, irritable bowel syndrome, celiac disease, systemic lupus erythematosus, obesity, depression, and schizophrenia. This is mainly due to the inflammatory response generated in response to the translocated microorganisms. Research has been conducted to develop therapies to decrease intestinal permeability in several diseases. This review summarizes knowledge related to pathways that regulate intestinal permeability, diseases associated with increased intestinal permeability, and advances in potential treatments.
{"title":"Regulation of Intestinal Permeability in Health and Disease: Possible Therapeutic Applications","authors":"Azmavet M. Güemes-González , Lourdes A. Arriaga-Pizano , Rommel Chacón-Salinas , Isabel Wong-Baeza , Eduardo Ferat-Osorio","doi":"10.1016/j.arcmed.2025.103321","DOIUrl":"10.1016/j.arcmed.2025.103321","url":null,"abstract":"<div><div>Intestinal permeability is the process by which certain substances pass through the intestinal barrier and enter the bloodstream to reach the tissues and organs where they are needed. This vital process is regulated by various physiological mechanisms, depending on the type of molecule being translocated, from ions and water molecules to large peptides and vitamins. However, under certain conditions, intestinal permeability can increase, exposing the body to the passage of unwanted molecules and pathogenic microorganisms. The various mechanisms involved in increased intestinal permeability include the zonulin pathway, intestinal epithelial cell death, intestinal dysbiosis, and transcytosis. Each of these mechanisms is activated by certain stimuli, and may occur in isolation or together. The translocation of molecules and pathogens has been linked to the development or worsening of certain pathologies, such as acute pancreatitis, sepsis, inflammatory bowel diseases, irritable bowel syndrome, celiac disease, systemic lupus erythematosus, obesity, depression, and schizophrenia. This is mainly due to the inflammatory response generated in response to the translocated microorganisms. Research has been conducted to develop therapies to decrease intestinal permeability in several diseases. This review summarizes knowledge related to pathways that regulate intestinal permeability, diseases associated with increased intestinal permeability, and advances in potential treatments.</div></div>","PeriodicalId":8318,"journal":{"name":"Archives of Medical Research","volume":"57 3","pages":"Article 103321"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-04-01Epub Date: 2025-09-18DOI: 10.1016/j.arcmed.2025.103327
Yasmine Boumerdassi , Vincent Puy , Solmaz Sarandi , Michael Grynberg , Maeliss Peigne , Christophe Sifer
{"title":"When There is More than Meets the Eye: It is Time to Team up with AI","authors":"Yasmine Boumerdassi , Vincent Puy , Solmaz Sarandi , Michael Grynberg , Maeliss Peigne , Christophe Sifer","doi":"10.1016/j.arcmed.2025.103327","DOIUrl":"10.1016/j.arcmed.2025.103327","url":null,"abstract":"","PeriodicalId":8318,"journal":{"name":"Archives of Medical Research","volume":"57 3","pages":"Article 103327"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145093016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-04-01Epub Date: 2025-10-03DOI: 10.1016/j.arcmed.2025.103325
Iwona Gawron , Justyna Brodowicz , Krzysztof Skotniczny , Robert Jach
Purpose
To investigate whether clinical and biochemical profiles, including inflammatory mediators, differ between hyperandrogenemia and normoandrogenemia in normogonadotropic anovulation, and to analyze the correlations of selected variables with inflammatory activity.
Methods
Clinical parameters, such as quality of life, and biochemical characteristics, including ovarian, metabolic and inflammatory parameters, were prospectively compared across hyperandrogenemia and normoandrogenemia groups of anovulatory women. Their correlations with interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), interleukin-10 (IL-10), and C-reactive protein (CRP) concentrations – potentially involved in ovulatory mechanisms – were assessed.
Results
The study groups did not differ significantly in terms of selected clinical, inflammatory, and metabolic parameters. Biochemically, the hyperandrogenemia group had significantly higher concentrations of follicle-stimulating hormone, luteinizing hormone, anti-Müllerian hormone, and free triiodothyronine. Testosterone concentration did not exhibit significant correlations with inflammatory indicators. The strongest correlations with IL-6, CRP, and TNF-α concentrations were found for metabolic parameters. Clinical parameters, such as quality of life in “Physical functioning” negatively correlated with IL-6 and CRP, while “Energy/Fatigue” correlated negatively with CRP concentration. Hyperandrogenism indicators, such as the Ferriman-Gallwey score and the free androgen index, positively correlated with IL-6 and CRP concentrations.
Conclusions
Hyperandrogenemia had no effect on clinical, metabolic, or inflammatory parameters. Since no differences in inflammatory parameters were found between hyperandrogenemia and normoandrogenemia, further investigation into the mechanisms of ovulatory defects is warranted. The observed correlations between clinical and metabolic parameters and inflammatory mediators were not driven by hyperandrogenemia. Reducing systemic inflammation and its chronicity is essential to prevent adverse metabolic health outcomes.
{"title":"Hyperandrogenaemia and Systemic Low-Grade Inflammation in Normogonadotropic Anovulation: A Prospective Cohort Study","authors":"Iwona Gawron , Justyna Brodowicz , Krzysztof Skotniczny , Robert Jach","doi":"10.1016/j.arcmed.2025.103325","DOIUrl":"10.1016/j.arcmed.2025.103325","url":null,"abstract":"<div><h3>Purpose</h3><div>To investigate whether clinical and biochemical profiles, including inflammatory mediators, differ between hyperandrogenemia and normoandrogenemia in normogonadotropic anovulation, and to analyze the correlations of selected variables with inflammatory activity.</div></div><div><h3>Methods</h3><div>Clinical parameters, such as quality of life, and biochemical characteristics, including ovarian, metabolic and inflammatory parameters, were prospectively compared across hyperandrogenemia and normoandrogenemia groups of anovulatory women. Their correlations with interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), interleukin-10 (IL-10), and C-reactive protein (CRP) concentrations – potentially involved in ovulatory mechanisms – were assessed.</div></div><div><h3>Results</h3><div>The study groups did not differ significantly in terms of selected clinical, inflammatory, and metabolic parameters. Biochemically, the hyperandrogenemia group had significantly higher concentrations of follicle-stimulating hormone, luteinizing hormone, anti-Müllerian hormone, and free triiodothyronine. Testosterone concentration did not exhibit significant correlations with inflammatory indicators. The strongest correlations with IL-6, CRP, and TNF-α concentrations were found for metabolic parameters. Clinical parameters, such as quality of life in “Physical functioning” negatively correlated with IL-6 and CRP, while “Energy/Fatigue” correlated negatively with CRP concentration. Hyperandrogenism indicators, such as the Ferriman-Gallwey score and the free androgen index, positively correlated with IL-6 and CRP concentrations.</div></div><div><h3>Conclusions</h3><div>Hyperandrogenemia had no effect on clinical, metabolic, or inflammatory parameters. Since no differences in inflammatory parameters were found between hyperandrogenemia and normoandrogenemia, further investigation into the mechanisms of ovulatory defects is warranted. The observed correlations between clinical and metabolic parameters and inflammatory mediators were not driven by hyperandrogenemia. Reducing systemic inflammation and its chronicity is essential to prevent adverse metabolic health outcomes.</div></div>","PeriodicalId":8318,"journal":{"name":"Archives of Medical Research","volume":"57 3","pages":"Article 103325"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145217717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-04-01Epub Date: 2025-10-04DOI: 10.1016/j.arcmed.2025.103305
Jennifer Reséndiz-Vazquez , Víctor Domínguez-Reyes , Eduardo Terán-Paredes , Nicole Madero-Franco , Antonieta Chávez-González , Abraham Majluf-Cruz , José Antonio Alvarado-Moreno
Background
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as COVID-19 disease has the ability to generate sequelae that extend for weeks or months, giving rise to long-term COVID-19 disease. This condition reduces patients’ quality of life and predisposes them to several alterations, including failures in the blood coagulation system. Our laboratory has previously demonstrated abnormalities in endothelial colony-forming cells (ECFCs) of patients recovered from COVID-19.
Objective
To analyze the functional state of ECFCs in patients who experienced venous thromboembolic disease (VTD) or arterial thrombosis (AT) during long COVID-19, or post-COVID condition (PCC).
Methods
We compared 35 samples of peripheral blood (PB) mononuclear cells (MNCs) from patients with a thrombotic event (who had a healthy lifestyle before infection and were vaccinated) with 10 healthy volunteers and 10 samples from patients with a history of recurrent unprovoked VTD (rVTD) after a COVID-19 infection. The samples were cryopreserved in our laboratory and matched by age 25–50 years old and sex. The frequency, morphological characteristics, proliferation and angiogenic ability of ECFCs were evaluated in all samples.
Results
There were no significant differences between male and female patients, and the laboratory data did not indicate risk factors for VTD or AT. The frequency of ECFCs was not different between controls and patients, but a reduced proliferative capacity, a high percentage of senescence and non-angiogenic activity were observed in VTD samples.
Conclusions
Our results demonstrate a strong association between VTD events in patients with PCC who had a healthy lifestyle prior to infection and ECFCs dysfunction.
{"title":"Deep Venous Thrombosis in Patients Recovered from COVID-19: A Long-Term Sequel","authors":"Jennifer Reséndiz-Vazquez , Víctor Domínguez-Reyes , Eduardo Terán-Paredes , Nicole Madero-Franco , Antonieta Chávez-González , Abraham Majluf-Cruz , José Antonio Alvarado-Moreno","doi":"10.1016/j.arcmed.2025.103305","DOIUrl":"10.1016/j.arcmed.2025.103305","url":null,"abstract":"<div><h3>Background</h3><div>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as COVID-19 disease has the ability to generate sequelae that extend for weeks or months, giving rise to long-term COVID-19 disease. This condition reduces patients’ quality of life and predisposes them to several alterations, including failures in the blood coagulation system. Our laboratory has previously demonstrated abnormalities in endothelial colony-forming cells (ECFCs) of patients recovered from COVID-19.</div></div><div><h3>Objective</h3><div>To analyze the functional state of ECFCs in patients who experienced venous thromboembolic disease (VTD) or arterial thrombosis (AT) during long COVID-19, or post-COVID condition (PCC).</div></div><div><h3>Methods</h3><div>We compared 35 samples of peripheral blood (PB) mononuclear cells (MNCs) from patients with a thrombotic event (who had a healthy lifestyle before infection and were vaccinated) with 10 healthy volunteers and 10 samples from patients with a history of recurrent unprovoked VTD (rVTD) after a COVID-19 infection. The samples were cryopreserved in our laboratory and matched by age 25–50 years old and sex. The frequency, morphological characteristics, proliferation and angiogenic ability of ECFCs were evaluated in all samples.</div></div><div><h3>Results</h3><div>There were no significant differences between male and female patients, and the laboratory data did not indicate risk factors for VTD or AT. The frequency of ECFCs was not different between controls and patients, but a reduced proliferative capacity, a high percentage of senescence and non-angiogenic activity were observed in VTD samples.</div></div><div><h3>Conclusions</h3><div>Our results demonstrate a strong association between VTD events in patients with PCC who had a healthy lifestyle prior to infection and ECFCs dysfunction.</div></div>","PeriodicalId":8318,"journal":{"name":"Archives of Medical Research","volume":"57 3","pages":"Article 103305"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145217718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-04-01Epub Date: 2025-09-18DOI: 10.1016/j.arcmed.2025.103315
Oscar Arias-Carrión , Héctor A. Cabrera-Fuentes
{"title":"Pharmacogenetics, Polypharmacy, and the Future of Safer Prescribing: From Population Insights to Clinical Action","authors":"Oscar Arias-Carrión , Héctor A. Cabrera-Fuentes","doi":"10.1016/j.arcmed.2025.103315","DOIUrl":"10.1016/j.arcmed.2025.103315","url":null,"abstract":"","PeriodicalId":8318,"journal":{"name":"Archives of Medical Research","volume":"57 3","pages":"Article 103315"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145092858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Previous studies have shown that hyperglycemia upregulates cyclin-dependent kinase 2 (CDK2) and its cyclin partners, cyclin E and cyclin A, in cholangiocarcinoma (CCA). However, the effects of targeting these proteins in a hyperglycemic state are unclear.
Aim
This study aimed to investigate the therapeutic effects of inhibiting CDK2 and its cyclin partners under high-glucose conditions.
Methods
CCA cells were cultured in normal glucose (NG) and high glucose (HG) conditions. Expression of CDK2 and the associated cyclins was analyzed using online public databases and verified by Western blot. Cell proliferation and cytotoxicity were determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and sulforhodamine B (SRB) assays. CDK2 activity was inhibited using tagtociclib. Cyclin E and cyclin A expression was suppressed using siRNA. Molecular mechanisms were analyzed using flow cytometry and Western blot.
Results
CDK2, cyclin E, and cyclin A were upregulated in CCA tissues and cells cultured in the HG condition compared with normal bile ducts. Tagtociclib significantly suppressed CCA cell growth, with HG cells being more sensitive than NG cells. Partial suppression of cyclin E and cyclin A expression minimally affected cell growth but significantly reduced the metastatic phenotypes of CCA cells by suppressing the epithelial-mesenchymal transition.
Conclusion
CCA cells with upregulated CDK2 and its cyclin partners in HG were more sensitive to tagtociclib at a higher dose. Cyclin E and cyclin A also regulated CCA metastasis by controlling epithelial-mesenchymal transition. Targeting CDK2 and its associated cyclins in CCA cells demonstrated therapeutic potential that requires further translational and clinical verification.
{"title":"Pro-Tumorigenic Roles of Cyclin Dependent Kinase 2 and its Associated Cyclins in Cholangiocarcinoma Progression under High Glucose Condition","authors":"Cheerapinya Taebprakhon , Supannika Sorin , Kullanat Khawkhiaw , Chatchai Phoomak , Wunchana Seubwai , Sopit Wongkham , Charupong Saengboonmee","doi":"10.1016/j.arcmed.2026.103383","DOIUrl":"10.1016/j.arcmed.2026.103383","url":null,"abstract":"<div><h3>Background</h3><div>Previous studies have shown that hyperglycemia upregulates cyclin-dependent kinase 2 (CDK2) and its cyclin partners, cyclin E and cyclin A, in cholangiocarcinoma (CCA). However, the effects of targeting these proteins in a hyperglycemic state are unclear.</div></div><div><h3>Aim</h3><div>This study aimed to investigate the therapeutic effects of inhibiting CDK2 and its cyclin partners under high-glucose conditions.</div></div><div><h3>Methods</h3><div>CCA cells were cultured in normal glucose (NG) and high glucose (HG) conditions. Expression of CDK2 and the associated cyclins was analyzed using online public databases and verified by Western blot. Cell proliferation and cytotoxicity were determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and sulforhodamine B (SRB) assays. CDK2 activity was inhibited using tagtociclib. Cyclin E and cyclin A expression was suppressed using siRNA. Molecular mechanisms were analyzed using flow cytometry and Western blot.</div></div><div><h3>Results</h3><div>CDK2, cyclin E, and cyclin A were upregulated in CCA tissues and cells cultured in the HG condition compared with normal bile ducts. Tagtociclib significantly suppressed CCA cell growth, with HG cells being more sensitive than NG cells. Partial suppression of cyclin E and cyclin A expression minimally affected cell growth but significantly reduced the metastatic phenotypes of CCA cells by suppressing the epithelial-mesenchymal transition.</div></div><div><h3>Conclusion</h3><div>CCA cells with upregulated CDK2 and its cyclin partners in HG were more sensitive to tagtociclib at a higher dose. Cyclin E and cyclin A also regulated CCA metastasis by controlling epithelial-mesenchymal transition. Targeting CDK2 and its associated cyclins in CCA cells demonstrated therapeutic potential that requires further translational and clinical verification.</div></div>","PeriodicalId":8318,"journal":{"name":"Archives of Medical Research","volume":"57 3","pages":"Article 103383"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146074004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-04-01Epub Date: 2025-09-18DOI: 10.1016/j.arcmed.2025.103302
Leonor Cuadra-LLopart , Samantha Santana Zorrilla , Daniel Martínez-Laguna , Mercè Giner , Rafael Izquierdo Aviñó , Ma Jose Montoya-Garcia , Diana Ovejero Crespo , Manuel Mesa Ramos , Sonia Castro Oreiro , Laura Fernández Sénder , Leticia Lojo-Oliveira , Carmen Gomez-Vaquero , Christian Alvarado Escobar , Ma Jesús Montesa , Teresa Pareja Sierra , Cristina Campos Fernández , Jose Cancio-Trujillo , Sonia Fuentes , Ma Jose Marassi-Campos , Guillermo Martinez Diaz-Guerra , Jesús Mora-Fernández
Background
Fracture Liaison Services (FLS) are the gold standard for secondary fracture prevention, but their characteristics vary depending on the care model. This study describes the differences between Orthogeriatric (FLS-ORT) and Bone Metabolism (FLS-MET) models in Spain, based on data from the national osteoporotic fracture registry.
Methods
We conducted a retrospective, multicenter cohort study including 8,962 patients aged ≥50 years with fragility fractures from 25 active FLS in Spain (2019–2023). Patients were classified based on the care model: FLS-ORT (n = 3,695) or FLS-MET (n = 5,267). Baseline characteristics, fracture types, treatment initiation, adherence, and 12-month outcomes were compared.
Results
FLS-ORT patients were older (85 vs. 78 years, p <0.001), had more comorbidities, and a higher risk of falls. Hip fractures were predominant in FLS-ORT (75.8%), while vertebral fractures were more frequent in FLS-MET (p <0.001). Time from fracture to FLS assessment was shorter in FLS-ORT (0.1 vs. 1.6 months, p <0.001). At 12 months, fracture recurrence was higher in FLS-ORT (7.7 vs. 5.5 per 100 patient-years), and mortality was significantly greater (p <0.0001). However, osteoporosis treatment initiation (84.6%) and adherence (85.2%) were comparable across models.
Conclusions
FLS are the gold standard for secondary fracture prevention. Both FLS care models (FLS-ORT and FLS-MET) were effective in reducing the risk of new fractures in patients and minimizing the impact on the quality of life of patients who suffer a fragility fracture. Future integration into a unified model assessing all fractures is anticipated.
{"title":"Health Outcomes in Fragility Fractures in the Spanish Registry of Osteoporotic Fractures According to the FLS Care Model","authors":"Leonor Cuadra-LLopart , Samantha Santana Zorrilla , Daniel Martínez-Laguna , Mercè Giner , Rafael Izquierdo Aviñó , Ma Jose Montoya-Garcia , Diana Ovejero Crespo , Manuel Mesa Ramos , Sonia Castro Oreiro , Laura Fernández Sénder , Leticia Lojo-Oliveira , Carmen Gomez-Vaquero , Christian Alvarado Escobar , Ma Jesús Montesa , Teresa Pareja Sierra , Cristina Campos Fernández , Jose Cancio-Trujillo , Sonia Fuentes , Ma Jose Marassi-Campos , Guillermo Martinez Diaz-Guerra , Jesús Mora-Fernández","doi":"10.1016/j.arcmed.2025.103302","DOIUrl":"10.1016/j.arcmed.2025.103302","url":null,"abstract":"<div><h3>Background</h3><div>Fracture Liaison Services (FLS) are the gold standard for secondary fracture prevention, but their characteristics vary depending on the care model. This study describes the differences between Orthogeriatric (FLS-ORT) and Bone Metabolism (FLS-MET) models in Spain, based on data from the national osteoporotic fracture registry.</div></div><div><h3>Methods</h3><div>We conducted a retrospective, multicenter cohort study including 8,962 patients aged ≥50 years with fragility fractures from 25 active FLS in Spain (2019–2023). Patients were classified based on the care model: FLS-ORT (<em>n</em> = 3,695) or FLS-MET (<em>n</em> = 5,267). Baseline characteristics, fracture types, treatment initiation, adherence, and 12-month outcomes were compared.</div></div><div><h3>Results</h3><div>FLS-ORT patients were older (85 vs. 78 years, <em>p</em> <0.001), had more comorbidities, and a higher risk of falls. Hip fractures were predominant in FLS-ORT (75.8%), while vertebral fractures were more frequent in FLS-MET (<em>p</em> <0.001). Time from fracture to FLS assessment was shorter in FLS-ORT (0.1 vs. 1.6 months, <em>p</em> <0.001). At 12 months, fracture recurrence was higher in FLS-ORT (7.7 vs. 5.5 per 100 patient-years), and mortality was significantly greater (<em>p</em> <0.0001). However, osteoporosis treatment initiation (84.6%) and adherence (85.2%) were comparable across models.</div></div><div><h3>Conclusions</h3><div>FLS are the gold standard for secondary fracture prevention. Both FLS care models (FLS-ORT and FLS-MET) were effective in reducing the risk of new fractures in patients and minimizing the impact on the quality of life of patients who suffer a fragility fracture. Future integration into a unified model assessing all fractures is anticipated.</div></div>","PeriodicalId":8318,"journal":{"name":"Archives of Medical Research","volume":"57 3","pages":"Article 103302"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145092885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-04-01Epub Date: 2026-02-09DOI: 10.1016/j.arcmed.2026.103399
SEBASTIANO RAVENDA , VIRGINIA BERETTA , ELENA SCARPA , CHIARA PETROLINI , VALENTINA DELL'ORTO , LUCA CARNEVALI , ANDREA SGOIFO , SERAFINA PERRONE
{"title":"Response to: Neonatal Autonomic and Adrenocorticotropic Features in the Offspring of Mothers in the Gestational Diabetes","authors":"SEBASTIANO RAVENDA , VIRGINIA BERETTA , ELENA SCARPA , CHIARA PETROLINI , VALENTINA DELL'ORTO , LUCA CARNEVALI , ANDREA SGOIFO , SERAFINA PERRONE","doi":"10.1016/j.arcmed.2026.103399","DOIUrl":"10.1016/j.arcmed.2026.103399","url":null,"abstract":"","PeriodicalId":8318,"journal":{"name":"Archives of Medical Research","volume":"57 3","pages":"Article 103399"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146159649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-04-01Epub Date: 2026-01-30DOI: 10.1016/j.arcmed.2026.103382
Julio Edgardo Gonzalez-Aguirre, Hector Alejandro Medina-Ramirez, Berenice Soto-Moncivais, Sofia Rebeca Sanchez-Ruiz, Carlos Garcia-Arroyo, Juan Francisco Moreno-Hoyos-Abril, Homero Nañez-Terreros
Purpose
Several studies have evaluated the use of interstitial flash glucose (IFG) monitors in critically ill patients. IFG offers potential advantages over capillary blood glucose (CBG) measurements. This study examined the agreement between IFG and CBG values in patients with multiple organ failure (MOF) who required vasopressors and were admitted to the intensive care unit (ICU).
Methods
This cross-sectional study included 394 pairs of CBG and IFG determinations corresponding to 11 ICU-admitted patients. All patients had MOF and required an IV vasopressor infusion. IFG accuracy against CBG was assessed using the Bland-Altman method and by calculating the median absolute relative difference (MARD). Clinical accuracy was assessed using the Clarke Consensus Error Grid (CEG).
Results
The MARD between IFG and CBG was –4.90 (IQR –18.05 to 9.75) mg/dL. Only 76 (19.3%) glucose pairs had MARD above the recommended value of 14%. A positive cumulative balance and intravenous insulin administration were associated with an increased MARD. Bland-Altman analysis revealed a mean difference of 4.79% (SD = 24.06%, 95% CI 2.34–7.24%), with upper and lower limits of agreement of 51.93% (95% CI 47.0–55.56%) and –42.36% (95% CI –46.7 to –37.9%), respectively. A total of 186 (49.9%) IFG were above the recommended threshold value of 12.5% compared to the CBG reference. Only 246 (62.6%) determinations were in the risk zone of the CEG.
Conclusion
IFG does not demonstrate analytical or clinical accuracy equivalent to CBG in patients with MOF requiring vasopressor infusion.
几项研究评估了间质瞬时血糖（IFG）监测仪在危重患者中的应用。IFG比毛细管血糖（CBG）测量具有潜在的优势。本研究检查了多器官衰竭（MOF）患者IFG和CBG值之间的一致性，这些患者需要血管加压药物并被送入重症监护病房（ICU）。方法本横断面研究包括11例icu住院患者的394对CBG和IFG测定。所有患者都有MOF，需要静脉输注血管加压素。使用Bland-Altman方法和计算中位数绝对相对差（MARD）来评估IFG对CBG的准确性。临床准确性评估使用克拉克共识误差网格（CEG）。结果IFG与CBG的MARD值为-4.90 (IQR值为-18.05 ~ 9.75)mg/dL。只有76（19.3%）对葡萄糖的MARD高于14%的推荐值。累积平衡阳性和静脉注射胰岛素与MARD增加有关。Bland-Altman分析显示平均差异为4.79% (SD = 24.06%, 95% CI 2.34-7.24%)，一致性上限和下限分别为51.93% （95% CI 47.0-55.56%）和-42.36% （95% CI -46.7 -37.9%）。与CBG参考值相比，共有186例（49.9%）IFG高于推荐阈值12.5%。只有246例（62.6%）处于CEG的危险区。结论：ifg在需要血管加压剂输注的MOF患者中没有显示出与CBG相当的分析或临床准确性。
{"title":"Comparability of Interstitial and Capillary Blood Glucose Values: A Cross-Sectional Study of Samples from Patients with Multiple Organ Failure","authors":"Julio Edgardo Gonzalez-Aguirre, Hector Alejandro Medina-Ramirez, Berenice Soto-Moncivais, Sofia Rebeca Sanchez-Ruiz, Carlos Garcia-Arroyo, Juan Francisco Moreno-Hoyos-Abril, Homero Nañez-Terreros","doi":"10.1016/j.arcmed.2026.103382","DOIUrl":"10.1016/j.arcmed.2026.103382","url":null,"abstract":"<div><h3>Purpose</h3><div>Several studies have evaluated the use of interstitial flash glucose (IFG) monitors in critically ill patients. IFG offers potential advantages over capillary blood glucose (CBG) measurements. This study examined the agreement between IFG and CBG values in patients with multiple organ failure (MOF) who required vasopressors and were admitted to the intensive care unit (ICU).</div></div><div><h3>Methods</h3><div>This cross-sectional study included 394 pairs of CBG and IFG determinations corresponding to 11 ICU-admitted patients. All patients had MOF and required an IV vasopressor infusion. IFG accuracy against CBG was assessed using the Bland-Altman method and by calculating the median absolute relative difference (MARD). Clinical accuracy was assessed using the Clarke Consensus Error Grid (CEG).</div></div><div><h3>Results</h3><div>The MARD between IFG and CBG was –4.90 (IQR –18.05 to 9.75) mg/dL. Only 76 (19.3%) glucose pairs had MARD above the recommended value of 14%. A positive cumulative balance and intravenous insulin administration were associated with an increased MARD. Bland-Altman analysis revealed a mean difference of 4.79% (SD = 24.06%, 95% CI 2.34–7.24%), with upper and lower limits of agreement of 51.93% (95% CI 47.0–55.56%) and –42.36% (95% CI –46.7 to –37.9%), respectively. A total of 186 (49.9%) IFG were above the recommended threshold value of 12.5% compared to the CBG reference. Only 246 (62.6%) determinations were in the risk zone of the CEG.</div></div><div><h3>Conclusion</h3><div>IFG does not demonstrate analytical or clinical accuracy equivalent to CBG in patients with MOF requiring vasopressor infusion.</div></div>","PeriodicalId":8318,"journal":{"name":"Archives of Medical Research","volume":"57 3","pages":"Article 103382"},"PeriodicalIF":3.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146074002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号